Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.

The use of CGM has been growing among people without diabetes, including those with prediabetes, particularly with the ...

Continuous glucose monitoring can identify unrecognized hyperglycemia and hypoglycemia in dialysis patients, challenging reliance on A1c for diabetes management.

After dealing with a deployment problem with glucose monitors earlier this year, interim CEO Jake Leach said improving ...

DexCom, Inc. DXCM reported third-quarter 2025 adjusted earnings per share (EPS) of 61 cents, which beat the Zacks Consensus ...

The market awaits DexCom's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter. It's important for new investors to u ...

DexCom, Inc. DXCM is scheduled to report third-quarter 2025 resultson Oct. 30, after the closing bell. In the last reported ...

Medical device company DexCom (NASDAQ:DXCM) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales ...

We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as ...

Analysts have set 12-month price targets for DexCom, revealing an average target of $97.15, a high estimate of $106.00, and a low estimate of $85.00. Experiencing a 4.33% decline, the current average ...

Amid some scrutiny over its latest-generation G7 CGM, Dexcom officials addressed claims on the company's latest earnings call ...

Continuous glucose monitors — the tiny sensors once reserved for people with diabetes — are now appearing on the arms of ...